IHP Therapeutics

Executive Summary

IHP Therapeutics is a private, clinical-stage biotechnology company developing IHP-102, a dual-mechanism drug candidate for acute vaso-occlusive crises (VOCs) in sickle cell disease. The company aims to address a critical unmet need by providing the first self-administered rescue therapy, shifting care from hospital to home. IHP-102's unique dual mechanism targets both sickling and inflammation, potentially offering rapid symptom relief and reduced healthcare burden. The company is headquartered in San Diego and has raised undisclosed funding. While still in early clinical development, IHP-102's differentiation as an at-home treatment positions it strongly in the sickle cell market, which lacks convenient outpatient options. Key risks include clinical trial execution, regulatory pathway, and competition from gene therapies and other novel agents. The upcoming catalysts will determine the program's viability and potential for partnership or acquisition.

Upcoming Catalysts (preview)

• Q1 2027Phase 1/2 interim safety and efficacy data for IHP-10240% success
• Q3 2026FDA alignment on pivotal trial design or special protocol assessment55% success
• TBDPotential partnership or licensing deal for IHP-10230% success